Our study identifies stage II-III melanoma patients at a high risk of BM and provides clinically useful information for tailoring follow-up.
Mandalà et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: